Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bora Pharmaceuticals Co's Ending Cash Position for the quarter that ended in Mar. 2026 was NT$4,832 Mil.
Bora Pharmaceuticals Co's quarterly Ending Cash Position
increased
from Sep. 2025 (NT$4,409 Mil) to Dec. 2025 (NT$5,077 Mil) but then
declined
from Dec. 2025 (NT$5,077 Mil) to Mar. 2026 (NT$4,832 Mil).
Bora Pharmaceuticals Co's annual Ending Cash Position
increased
from Dec. 2023 (NT$3,053 Mil) to Dec. 2024 (NT$5,829 Mil) but then
declined
from Dec. 2024 (NT$5,829 Mil) to Dec. 2025 (NT$5,077 Mil).
Bora Pharmaceuticals Co Ending Cash Position Related Terms
Bora Pharmaceuticals Co Ending Cash Position Historical Data
* Premium members only.
The historical data trend for Bora Pharmaceuticals Co's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bora Pharmaceuticals Co Ending Cash Position Chart
Bora Pharmaceuticals Co Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Bora Pharmaceuticals Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of NT$4,832 Mil mean?
Bora Pharmaceuticals Co (TPE:6472) has a Ending Cash Position of NT$4,832 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bora Pharmaceuticals Co and its competitors.
Is Bora Pharmaceuticals Co's Ending Cash Position too high?
Bora Pharmaceuticals Co's current Ending Cash Position is NT$4,832 Mil. Overall, Bora Pharmaceuticals Co has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's Ending Cash Position compare to ZTS?
Bora Pharmaceuticals Co's Ending Cash Position of NT$4,832 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bora Pharmaceuticals Co and its competitors. Bora Pharmaceuticals Co's current Ending Cash Position is NT$4,832 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$747.64, compared to a current price of NT$445.50 — trading 40.4% below its estimated fair value. The current Ending Cash Position is NT$4,832 Mil. Bora Pharmaceuticals Co's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current Ending Cash Position is NT$4,832 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$445.50 is trading 40.4% below its estimated GF Value™ of NT$747.64.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for TPE:6472:
Ending Cash Position: NT$4,832 Mil
GF Value™: NT$747.64 vs. price of NT$445.50 (40.4% below fair value)
No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
85GF Score
Get the complete analysis for TPE:6472
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6472 has been successfully added to your 
